Literature DB >> 22296587

Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.

D Scott Wilbur1, Ming-Kuan Chyan, Hirohisa Nakamae, Yun Chen, Donald K Hamlin, Erlinda B Santos, Brian T Kornblit, Brenda M Sandmaier.   

Abstract

We are investigating the use of an (211)At-labeled anti-CD45 monoclonal antibody (mAb) as a replacement of total body irradiation in conditioning regimens designed to decrease the toxicity of hematopoietic cell transplantation (HCT). As part of that investigation, dose-escalation studies were conducted in dogs using (211)At-labeled anticanine CD45 mAb, CA12.10C12, conjugated with a maleimido-closo-decaborate(2-) derivative, 4. Unacceptable renal toxicity was noted in the dogs receiving doses in the 0.27-0.62 mCi/kg range. This result was not anticipated, as no toxicity had been noted in prior biodistribution and toxicity studies conducted in mice. Studies were conducted to understand the cause of the renal toxicity and to find a way to circumvent it. A dog biodistribution study was conducted with (123)I-labeled CA12.10C12 that had been conjugated with 4. The biodistribution data showed that 10-fold higher kidney concentrations were obtained with the maleimido-conjugate than had been obtained in a previous biodistribution study with (123)I-labeled CA12.10C12 conjugated with an amine-reactive phenylisothiocyanato-CHX-A″ derivative. The difference in kidney concentrations observed in dogs for the two conjugation approaches led to an investigation of the reagents. SE-HPLC analyses showed that the purity of the CA12.10C12 conjugated via reduced disulfides was lower than that obtained with amine-reactive conjugation reagents, and nonreducing SDS-PAGE analyses indicated protein fragments were present in the disulfide reduced conjugate. Although we had previously prepared closo-decaborate(2-) derivatives with amine-reactive functional groups (e.g., 6 and 8), a new, easily synthesized, amine-reactive (phenylisothiocyanate) derivative, 10, was prepared for use in the current studies. A biodistribution was conducted with coadministered (125)I- and (211)At-labeled CA12.10C10 conjugated with 10. In that study, lower kidney concentrations were obtained for both radionuclides than had been obtained in the earlier study of the same antibody conjugated with 4 after reduction of disulfide bonds.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22296587      PMCID: PMC3310299          DOI: 10.1021/bc200401b

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  24 in total

1.  Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study.

Authors:  Wolfgang A Bethge; D Scott Wilbur; Rainer Storb; Donald K Hamlin; Erlinda B Santos; Martin W Brechbiel; Brenda M Sandmaier
Journal:  Transplantation       Date:  2004-08-15       Impact factor: 4.939

2.  Specific marrow localization of an 131I-labeled anti-myeloid antibody in normal dogs: effects of a "cold" antibody pretreatment dose on marrow localization.

Authors:  J A Bianco; B Sandmaier; P A Brown; C Badger; I Bernstein; J Eary; L Durack; F Schuening; R Storb; F Appelbaum
Journal:  Exp Hematol       Date:  1989-10       Impact factor: 3.084

3.  Durable donor engraftment after radioimmunotherapy using α-emitter astatine-211-labeled anti-CD45 antibody for conditioning in allogeneic hematopoietic cell transplantation.

Authors:  Yun Chen; Brian Kornblit; Donald K Hamlin; George E Sale; Erlinda B Santos; D Scott Wilbur; Barry E Storer; Rainer Storb; Brenda M Sandmaier
Journal:  Blood       Date:  2011-12-01       Impact factor: 22.113

4.  Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.

Authors:  M R Zalutsky; P K Garg; H S Friedman; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

5.  Sulfhydryl site-specific cross-linking and labeling of monoclonal antibodies by a fluorescent equilibrium transfer alkylation cross-link reagent.

Authors:  R B del Rosario; R L Wahl; S J Brocchini; R G Lawton; R H Smith
Journal:  Bioconjug Chem       Date:  1990 Jan-Feb       Impact factor: 4.774

6.  Influence of antibody isotype on passive serotherapy of lymphoma.

Authors:  E Y Denkers; C C Badger; J A Ledbetter; I D Bernstein
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

7.  Biotin reagents in antibody pretargeting. 6. Synthesis and in vivo evaluation of astatinated and radioiodinated aryl- and nido-carboranyl-biotin derivatives.

Authors:  D Scott Wilbur; Donald K Hamlin; Ming-Kuan Chyan; Brian B Kegley; Janna Quinn; Robert L Vessella
Journal:  Bioconjug Chem       Date:  2004 May-Jun       Impact factor: 4.774

8.  Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Brian B Kegley; Reudi Risler; Pradip M Pathare; Janna Quinn; Robert L Vessella; Catherine Foulon; Michael Zalutsky; Timothy J Wedge; M Frederick Hawthorne
Journal:  Bioconjug Chem       Date:  2004 Jan-Feb       Impact factor: 4.774

9.  Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts.

Authors:  Brenda M Sandmaier; Wolfgang A Bethge; D Scott Wilbur; Donald K Hamlin; Erlinda B Santos; Martin W Brechbiel; Darrell R Fisher; Rainer Storb
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

10.  Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate.

Authors:  M R Zalutsky; A S Narula
Journal:  Int J Rad Appl Instrum A       Date:  1988
View more
  19 in total

1.  Conditioning with α-emitter based radioimmunotherapy in canine allogeneic hematopoietic cell transplantation.

Authors:  Brian Kornblit; Yun Chen; Brenda M Sandmaier
Journal:  Chimerism       Date:  2012-04-01

2.  Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model.

Authors:  Damian J Green; Mazyar Shadman; Jon C Jones; Shani L Frayo; Aimee L Kenoyer; Mark D Hylarides; Donald K Hamlin; D Scott Wilbur; Ethan R Balkan; Yukang Lin; Brian W Miller; Sofia H L Frost; Ajay K Gopal; Johnnie J Orozco; Theodore A Gooley; Kelly L Laird; Brian G Till; Tom Bäck; Brenda M Sandmaier; John M Pagel; Oliver W Press
Journal:  Blood       Date:  2015-01-27       Impact factor: 22.113

3.  The α-emitter astatine-211 targeted to CD38 can eradicate multiple myeloma in a disseminated disease model.

Authors:  Shyril O'Steen; Melissa L Comstock; Johnnie J Orozco; Donald K Hamlin; D Scott Wilbur; Jon C Jones; Aimee Kenoyer; Margaret E Nartea; Yukang Lin; Brian W Miller; Theodore A Gooley; Sherilyn A Tuazon; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; Oliver W Press; Damian J Green
Journal:  Blood       Date:  2019-10-10       Impact factor: 22.113

4.  (211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy.

Authors:  Christopher R Burtner; Devikha Chandrasekaran; Erlinda B Santos; Brian C Beard; Jennifer E Adair; Donald K Hamlin; D Scott Wilbur; Brenda M Sandmaier; Hans-Peter Kiem
Journal:  Hum Gene Ther       Date:  2015-06       Impact factor: 5.695

5.  Anti-CD45 radioimmunotherapy using (211)At with bone marrow transplantation prolongs survival in a disseminated murine leukemia model.

Authors:  Johnnie J Orozco; Tom Bäck; Aimee Kenoyer; Ethan R Balkin; Donald K Hamlin; D Scott Wilbur; Darrell R Fisher; Shani L Frayo; Mark D Hylarides; Damian J Green; Ajay K Gopal; Oliver W Press; John M Pagel
Journal:  Blood       Date:  2013-03-07       Impact factor: 22.113

6.  α-Imaging Confirmed Efficient Targeting of CD45-Positive Cells After 211At-Radioimmunotherapy for Hematopoietic Cell Transplantation.

Authors:  Sofia H L Frost; Brian W Miller; Tom A Bäck; Erlinda B Santos; Donald K Hamlin; Sue E Knoblaugh; Shani L Frayo; Aimee L Kenoyer; Rainer Storb; Oliver W Press; D Scott Wilbur; John M Pagel; Brenda M Sandmaier
Journal:  J Nucl Med       Date:  2015-09-03       Impact factor: 10.057

Review 7.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

8.  Site-specific radioiodination of an anti-HER2 single domain antibody fragment with a residualizing prosthetic agent.

Authors:  Yutian Feng; Zhengyuan Zhou; Darryl McDougald; Rebecca L Meshaw; Ganesan Vaidyanathan; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2020-05-12       Impact factor: 2.408

9.  Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer.

Authors:  Yawen Li; Ming-Kuan Chyan; Donald K Hamlin; Holly Nguyen; Robert Vessella; D Scott Wilbur
Journal:  Nucl Med Biol       Date:  2020-05-03       Impact factor: 2.408

10.  Addition of Astatine-211-Labeled Anti-CD45 Antibody to TBI as Conditioning for DLA-Identical Marrow Transplantation: A Novel Strategy to Overcome Graft Rejection in a Canine Presensitization Model: "Radioimmunotherapy to Overcome Transfusion-Induced Sensitization".

Authors:  Aya Nakaya; Huiying Qiu; Erlinda B Santos; Donald K Hamlin; D Scott Wilbur; Rainer Storb; Brenda M Sandmaier
Journal:  Transplant Cell Ther       Date:  2021-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.